Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive strategy.

Use of the investigational drug efruxifermin did not significantly reduce fibrosis in patients with compensated cirrhosis ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Cambridge, Massachusetts-based Vor Bio has confirmed that it will halt clinical and manufacturing operations, including its ...

Merck Animal Health is investing $895 million in its Kansas facility. Novo Nordisk anticipates Wegovy sales recovery ...

Global type 1 diabetes market is estimated to be valued at USD 16.97 Bn in 2025 and is expected to reach USD 26.22 Bn by 2032 ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention. Helen Coffey speaks to the dentists warning that jabs could have a worrying im ...

Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.